- Home
- UNCY vs GALT Comparison
UNCY vs GALT Comparison
Compare UNCY & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- GALT
- Stock Information
- Founded
- UNCY 2016
- GALT 2000
- Country
- UNCY United States
- GALT United States
- Employees
- UNCY N/A
- GALT N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- UNCY Health Care
- GALT Health Care
- Exchange
- UNCY Nasdaq
- GALT Nasdaq
- Market Cap
- UNCY 91.0M
- GALT 83.5M
- IPO Year
- UNCY 2021
- GALT N/A
- Fundamental
- Price
- UNCY $4.55
- GALT $2.18
- Analyst Decision
- UNCY Strong Buy
- GALT Buy
- Analyst Count
- UNCY 4
- GALT 2
- Target Price
- UNCY $63.75
- GALT $6.00
- AVG Volume (30 Days)
- UNCY 1.5M
- GALT 1.4M
- Earning Date
- UNCY 08-13-2025
- GALT 08-12-2025
- Dividend Yield
- UNCY N/A
- GALT N/A
- EPS Growth
- UNCY N/A
- GALT N/A
- EPS
- UNCY N/A
- GALT N/A
- Revenue
- UNCY N/A
- GALT N/A
- Revenue This Year
- UNCY N/A
- GALT N/A
- Revenue Next Year
- UNCY $1,458.53
- GALT N/A
- P/E Ratio
- UNCY N/A
- GALT N/A
- Revenue Growth
- UNCY N/A
- GALT N/A
- 52 Week Low
- UNCY $2.02
- GALT $0.73
- 52 Week High
- UNCY $11.00
- GALT $3.90
- Technical
- Relative Strength Index (RSI)
- UNCY 39.53
- GALT 56.30
- Support Level
- UNCY $4.76
- GALT $2.08
- Resistance Level
- UNCY $7.15
- GALT $2.66
- Average True Range (ATR)
- UNCY 0.97
- GALT 0.53
- MACD
- UNCY -0.28
- GALT -0.02
- Stochastic Oscillator
- UNCY 7.37
- GALT 33.07
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.